Issue 42, 2017

Decoration of trastuzumab with short oligonucleotides: synthesis and detailed characterization

Abstract

Trastuzumab (Herceptin®) is an FDA-approved therapeutic antibody currently employed in the treatment of metastatic stages of breast cancer. Herein, we propose a simple, fast and cost-effective methodology to conjugate trastuzumab with 22-mer 5′ thiol-modified oligonucleotides using a bifunctional crosslinker. The conjugates were successfully characterized by MALDI-ToF MS and SDS-PAGE, obviating the need for enzymatic digestion and difficult chromatographic separations. Furthermore, ELISA was performed to ensure that trastuzumab activity is not affected by oligonucleotide conjugation.

Graphical abstract: Decoration of trastuzumab with short oligonucleotides: synthesis and detailed characterization

Supplementary files

Article information

Article type
Paper
Submitted
03 Ndz 2017
Accepted
09 Nhl 2017
First published
09 Nhl 2017

Org. Biomol. Chem., 2017,15, 8923-8928

Decoration of trastuzumab with short oligonucleotides: synthesis and detailed characterization

A. M. Carvalho, A. Manicardi, C. V. Montes, S. B. Gunnoo, R. J. Schneider and A. Madder, Org. Biomol. Chem., 2017, 15, 8923 DOI: 10.1039/C7OB02216F

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements